CCL17 and CCL22 and their common receptor CCR4 seem to be associated with the promotion of inflammation in liver chronic diseases, Treg recruitment, and HCC promotion (35–37), and its repression could be another positive action of bemcentinib administration. Here, CCL22 is linked to hepatocellular carcinoma.